SNV1521 not checked

ParVation Therapeutics, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
2 active
2 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“SNV1521 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.”In the company’s words, NCT06220864 on ClinicalTrials.gov
Tested for
Advanced Solid Tumor, Pancreatic Cancer, Pancreatic Acinar Carcinoma
Main trialPhase 1
“This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the most effective and safe one. They are also investigating whether it can be combined with other cancer therapies.”In the company’s words, NCT06220864 on ClinicalTrials.gov
Other names
PARP inhibitor

Other drugs for Advanced Solid Tumor

All 2439 drugs for Advanced Solid Tumor

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 1Recruiting Dec 2027 SNV1521 in Participants With Advanced Solid Tumors
Phase 1Recruiting 1 Jun 2029 First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow SNV1521

Following is part of Solo: you see every change to SNV1521 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in